|
Market Closed -
Nasdaq
23:00:00 19/08/2026 +03
|
5-day change | 1st Jan Change | ||
| 2.230 USD | +9.85% |
|
+7.73% | +62.77% |
| 08-13 | Allogene Therapeutics Remains Attractive Given Valuation, Clinical Strategy, RBC Says | MT |
| 08-13 | Allogene Therapeutics, Inc., Q2 2026 Earnings Call, Aug 12, 2026 |
Company Valuation: Allogene Therapeutics, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 2,126 | 907.1 | 540.2 | 446.6 | 307.9 | 770.4 | - | - |
| Change | - | -57.34% | -40.45% | -17.32% | -31.06% | 150.24% | - | - |
| Enterprise Value (EV) 1 | 1,317 | 330.6 | 91.47 | 234.8 | 347 | 573.9 | 620.3 | 439.3 |
| Change | - | -74.89% | -72.33% | 156.69% | 47.8% | 65.38% | 8.08% | -29.17% |
| P/E | -7.89x | -2.71x | -1.54x | -1.61x | -1.57x | -3.69x | -3.47x | -3.99x |
| PBR | 2.32x | 1.36x | 1.06x | 1.07x | 1.07x | 1.93x | 3.87x | 1.73x |
| PEG | - | -0.1x | 0.16x | 0x | 0x | 0.1x | -0.54x | 0.3x |
| Capitalization / Revenue | 55.2x | 3,733x | 5,686x | 20,300x | - | 227x | 63.7x | 9.1x |
| EV / Revenue | 34.2x | 1,361x | 963x | 10,673x | - | 169x | 51.3x | 5.19x |
| EV / EBITDA | -5.37x | -1.03x | -0.29x | -0.96x | -1.76x | -2.87x | -2.59x | -1.62x |
| EV / EBIT | -5.15x | -0.99x | -0.28x | -0.91x | -1.66x | -2.88x | -2.66x | -2.01x |
| EV / FCF | -6.38x | -1.46x | -0.38x | -1.17x | -2.32x | -4.54x | -4.25x | -3.5x |
| FCF Yield | -15.7% | -68.3% | -262% | -85.6% | -43.1% | -22% | -23.5% | -28.6% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -1.89 | -2.32 | -2.09 | -1.32 | -0.87 | -0.6036 | -0.642 | -0.5596 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 38.49 | 0.243 | 0.095 | 0.022 | - | 3.4 | 12.09 | 84.64 |
| EBITDA 1 | -245.3 | -321.2 | -313.5 | -243.8 | -197 | -200.2 | -239.7 | -271.5 |
| EBIT 1 | -255.8 | -335.4 | -327.7 | -257.5 | -209.3 | -199.1 | -232.9 | -218.3 |
| Net income 1 | -257 | -332.6 | -327.3 | -257.6 | -190.9 | -185.1 | -219.8 | -212.4 |
| Net Debt 1 | -809.5 | -576.5 | -448.7 | -211.8 | 39.16 | -196.5 | -150.2 | -331.1 |
| Reference price 2 | 14.920 | 6.290 | 3.210 | 2.130 | 1.370 | 2.230 | 2.230 | 2.230 |
| Nbr of stocks (in thousands) | 142,516 | 144,210 | 168,277 | 209,672 | 224,730 | 345,491 | - | - |
| Announcement Date | 2/23/22 A | 2/28/23 A | 3/14/24 A | 3/13/25 A | 3/12/26 A | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -3.69x | 168.8x | -2.87x | -.--% | 770M | |
| 21.6x | 7.56x | 15.41x | 1.37% | 72.21B | |
| 36.46x | 9.42x | 28.89x | 0.04% | 63.98B | |
| -82.59x | 15.45x | -74.5x | -.--% | 28.53B | |
| 31.75x | 6.24x | 16.52x | -.--% | 25.07B | |
| -17.57x | 7.2x | -9.35x | -.--% | 28.42B | |
| 27.22x | 5.11x | 17.13x | -.--% | 20.04B | |
| 52.91x | 19.58x | 39.65x | 0.29% | 18.19B | |
| 7705.33x | 40.58x | -1416.2x | -.--% | 15.96B | |
| 16.82x | 4.99x | 11.65x | -.--% | 13.48B | |
| Average | 778.82x | 28.49x | -137.37x | 0.17% | 28.66B | |
| Weighted average by Cap. | 441.42x | 11.35x | -71.16x | 0.37% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- ALLO Stock
- Valuation Allogene Therapeutics, Inc.
Select your edition
All financial news and data tailored to specific country editions
